

# Adaptive protocols based on predictions from a mechanistic model of the effect of IL7 on CD4 counts

Laura Villain, Daniel Commenges, Mélanie Prague, Chloé Pasin, Rodolphe

Thiébaut

## ▶ To cite this version:

Laura Villain, Daniel Commenges, Mélanie Prague, Chloé Pasin, Rodolphe Thiébaut. Adaptive protocols based on predictions from a mechanistic model of the effect of IL7 on CD4 counts. International Biometric Conference, Jul 2018, Bacelone, Spain. hal-01973877

# HAL Id: hal-01973877 https://hal.inria.fr/hal-01973877

Submitted on 8 Jan 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés. Adaptive protocols based on predictions from a mechanistic model of the effect of IL7 on CD4 counts

L. Villain<sup>1,2,3\*</sup>, D. Commenges<sup>1,2,3</sup>, M. Prague<sup>1,2,3</sup>, C. Pasin<sup>1,2,3</sup>, R. Thiébaut<sup>1,2,3</sup>

<sup>1</sup>INRIA Bordeaux Sud-Ouest, SISTM team, Talence, France <sup>2</sup>Univ. Bordeaux, centre INSERM U1219 BPH, Bordeaux, France <sup>3</sup>Vaccine Research Institute, Créteil, France

IBC, Barcelona, July 2018



Villain, Commenges, Prague, Pasin, Thiébaut

Modeling the effect of IL7

# Introduction and context

- Some HIV-infected patients are unable to restore their levels of CD4 + T cells (CD4).
- IL7 is a cytokine produced by the organism (stromal cells).
- Injections of IL7 could help the reconstitution of the immune system.
- The aim is to maintain the patient above 500 CD4/ $\mu$ L of blood.

Context

4/29

• The first clinical trial on IL7 show positive results (Sereti Blood 2009, Levy CID 2012, Levy JCI 2009).



- Repeated cycle are necessary.
- Best adaptive protocol yet to determine.



- Data from phase I / II trials : INSPIRE 1, 2 and 3.
- 138 HIV-infected patients.
- Regular measurements of immunologic markers.



Figure – Design of INSPIRE 2 and 3 studies (ORI protocol)

(日) (同) (三) (三)

#### Mechanistic model

• Model the different cell populations, as shown in the following figure with the CD4 population.



Figure – P : proliferative CD4, R : resting CD4

$$\begin{cases} \frac{dR}{dt} = \lambda - \pi R + 2\rho P - \mu_R R, \\ \frac{dP}{dt} = \pi R - \rho P - \mu_P P, \end{cases}$$
(1)

•  $\lambda$  is the cell production rate,  $\pi$  is the proliferating rate,  $\rho$  is the return to resting state rate,  $\mu_R$  is the death rate of resting cells and  $\mu_P$  is the death rate of proliferative cells.

- Mechanistic model with biological parameters : one set of parameters means one trajectory
- Effect of the IL7 on the proliferation ( $\pi$ ) and cellular death ( $\mu_R$ )
- Random effects on the production and reversion rates ( $\lambda$  and  $\rho$ )
- There is a measurement error

Table -Parameters of the model and their estimation from Jarne et al.2018

		Lotimation
oduction rate	days <sup>-1</sup>	5.32 (0.33)
version rate	$cells.days^{-1}$	2.44 (0.23)
oliferation rate	$cells.days^{-1}$	0.058 (0.004)
ath rate of P cells	$cells.days^{-1}$	0.074 (0.005)
ath rate of R cells	$cells.days^{-1}$	0.077 (0.015)
fect of IL7 on $\pi$ (Inj1)	$days^{-1}.\mu g^{-1}$	0.93 (0.04)
fect of IL7 on $\pi$ (Inj2)	${\sf days^{-1}}.\mu g^{-1}$	0.707 (0.04)
fect of IL7 on $\pi$ (Inj3)	${\sf days^{-1}}.\mu g^{-1}$	0.229 (0.04)
fect of IL7 on $\mu_R$	cells.days $^{-1}$ . $\mu g^{-1}$	-0.08 (0.006)
cle effect of IL7	$days^{-1}$	-0.163 (0.015)
of the random effect on $\lambda$	days <sup>-1</sup>	0.243 (0.026)
of the random effect on $ ho$	$cells.days^{-1}$	0.515 (0.084)
ror of measurement on CD4	cells <sup>0.25</sup>	0.289 (0.003)
ror of measurement on P	cells <sup>0</sup> 25 <	0.281 (0.019)
	oduction rate version rate oliferation rate eath rate of P cells eath rate of R cells fect of IL7 on $\pi$ (Inj1) fect of IL7 on $\pi$ (Inj2) fect of IL7 on $\pi$ (Inj3) fect of IL7 on $\mu_R$ cle effect of IL7 of the random effect on $\lambda$ of the random effect on $\rho$ ror of measurement on CD4 ror of measurement on P	oduction ratedays^{-1}version ratecells.days^{-1}oliferation ratecells.days^{-1}oliferation ratecells.days^{-1}eath rate of P cellscells.days^{-1}eath rate of R cellscells.days^{-1}fect of IL7 on $\pi$ (Inj1)days^{-1}. $\mu g^{-1}$ fect of IL7 on $\pi$ (Inj2)days^{-1}. $\mu g^{-1}$ fect of IL7 on $\pi$ (Inj3)days^{-1}. $\mu g^{-1}$ fect of IL7 on $\pi$ (Inj3)days^{-1}. $\mu g^{-1}$ fect of IL7 on $\pi$ (Inj3)days^{-1}. $\mu g^{-1}$ fect of IL7 on $\mu_R$ cells.days^{-1}cle effect of IL7days^{-1}of the random effect on $\lambda$ days^{-1}of the random effect on $\rho$ cells.days^{-1}or of measurement on CD4cells^{0.25}ror of measurement on Pcells^{0.25} + 0 + 4 = +

9/29



Figure – Evolution of the total number of CD4 cells (cells/ $\mu$ L) on a patient after IL7 injections. Black line : fit predicted by NIMROD. Red dots : observations. Red lines : injections times.

Image: A math a math

# Adaptive Protocols.

∃ ► < ∃ ►</p>

The criterion of 550 CD4 for a new injection is **not adapted** to the patient :

- For those with a fast decrease of CD4 after an injection, the limit might be **too low** and then they risk to spend too much **time under 500 CD4**
- For those with a slow decrease of CD4 after an injection, the limit might be **too high** and then have **unnecessary cycles** of injection

To solve those issues, we propose four adaptive protocols.

- We want to keep the level of CD4 above the level of  $500CD4/\mu L$  of blood, but without too many injections.
- A mechanistic model was developed to show the effect of IL7 on the population of CD4 T cells.
- With this model, we use an MCMC algorithm to estimate the individual parameters to personalized the IL7 injections.

We have two ways of optimizing :

- We can still keep a visit every 3 month and predict the risk to be under 500 CD4 at the next visit. (Adaptive Criterion of Injection = ACI).
- Or we can predict the time when the patient will be at 500 CD4 and adapt the time of the next visit. (Adaptive Time of Injection = ATI).



Method



16/29

Villain, Commenges, Prague, Pasin, Thiébaut

Modeling the effect of IL7





<ロト <回ト < 回ト

∢ 臣 ≯

æ

Villain, Commenges, Prague, Pasin, Thiébaut Modeling the effect of IL7





(日)

< 三→

æ

Villain, Commenges, Prague, Pasin, Thiébaut Modeling the effect of IL7



æ



<ロト <回ト < 回ト

∢ 臣 ≯

æ



21/29

ъ

э

э

#### Adaptive protocols



#### Adaptive protocols

Duta a	nd protocol	s MC	MC Proto	cols parameters
Time				
90				
CD4				
740				
Ki67				
11				
niection	•			
0	•			
UPLOA	DI			
Time	CD4	Ki67	Injections	
0.00	450.00	10.00	1.00	
7.00	700.00	12.00	1.00	
	950.00	18.00	1.00	
14.00				
14.00 90.00	740.00	11.00	0.00	
14.00 90.00 Visit time	740.00	11.00	0.00	



N LE PERPERTENCE

Decision ACI: Pas d'injection, prochaine visite dans 3 mois Decision ACIC: Pas d'injection, prochaine visite dans 3 mois Decision ATI: Pas d'injections, visite dans 99 jours Decision ATIC: Pas d'injections, visite dans 99 jours

- The adaptive protocols showed a strong diminution of the time spent under 500 without an increase of the number of injections.
- Shiny app under development to have an easy interface.
- This protocol could be tested in a clinical trial.

# Thank you for your attention

## Method

Evolution of the estimation of Lambda



Villain, Commenges, Prague, Pasin, Thiébaut

Modeling the effect of IL7

- For the patient *i*, each iteration q of the MCMC gives a couple  $(\lambda_q, \rho_q)_i$
- Each couple of parameters gives a trajectory of CD4 :  $CD4_{iq}(t) = [P(t, \xi^{iq}) + Q(t, \xi^{iq})]$
- At each time point  $t_{ij}$  we have the distribution of CD4 and the distribution of the observations by adding an error of measurement :  $Y_{1jq}^i = [P(t_{ij}, \xi^{iq}) + Q(t_{ij}, \xi^{iq})]^{0.25} + \epsilon_{1jq}^i$

#### Prediction ability on real patients



28/29

Villain, Commenges, Prague, Pasin, Thiébaut

Modeling the effect of IL7

#### Prediction ability on real patients



29/29